Holen Sie sich die Stockscreener-App
4.78
2.05%
-0.10
Schlusskurs vom Vortag:
$4.88
Offen:
$4.91
24-Stunden-Volumen:
9,871
Relative Volume:
0.26
Marktkapitalisierung:
$223.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-1.65%
1M Leistung:
-0.21%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.75
$4.94
1-Wochen-Bereich:
$4.55
$4.94
52-Wochen-Spanne:
$3.4341
$5.10
Capsovision Inc Stock (CV) Company Profile
Firmenname
Capsovision Inc
Sektor
Branche
Telefon
(408) 370-4790
Adresse
18805 COX AVENUE SUITE 250, SARATOGA
Vergleichen Sie CV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CV
Capsovision Inc
|
4.78 | 228.26M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
123.84 | 214.96B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.59 | 149.24B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
358.16 | 136.23B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
90.20 | 116.33B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.07 | 48.41B | 5.88B | 1.34B | 577.90M | 2.3455 |
Capsovision Inc Stock (CV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Eingeleitet | Roth Capital | Buy |
| 2025-07-28 | Eingeleitet | The Benchmark Company | Speculative Buy |
Capsovision Inc Aktie (CV) Neueste Nachrichten
CapsoVision appoints David Garcia as SVP of finance By Investing.com - Investing.com South Africa
CapsoVision appoints David Garcia as SVP of finance - Investing.com
CapsoVision Appoints David Garcia as Finance VP - TipRanks
CapsoVision Appoints David Garcia as Senior Vice President of Finance - The Globe and Mail
CapsoVision (NASDAQ: CV) names David Garcia SVP of Finance; ex-Matterport FP&A VP - Stock Titan
CapsoVision to Release Third Quarter 2025 Financial Results on Thursday, November 13, 2025 - The Manila Times
CapsoVision (NASDAQ: CV) sets earnings results for Nov. 13; call at 4:30 ET with webcast - Stock Titan
CapsoVision (NASDAQ:CV) & Bioventus (NASDAQ:BVS) Critical Review - Defense World
Weiss Ratings Reaffirms "Sell (E-)" Rating for CapsoVision (NASDAQ:CV) - MarketBeat
CapsoVision prices $27.5M IPO - MSN
Reviewing Bioventus (NASDAQ:BVS) and CapsoVision (NASDAQ:CV) - Defense World
CapsoVision, Inc. (NASDAQ:CV) Short Interest Update - MarketBeat
CapsoVision CFO Lundquist steps down - MSN
CapsoVision's (CV) Sell (E-) Rating Reiterated at Weiss Ratings - MarketBeat
Analyzing Vyome (NASDAQ:HIND) and CapsoVision (NASDAQ:CV) - Defense World
Head to Head Survey: Vyome (NASDAQ:HIND) versus CapsoVision (NASDAQ:CV) - Defense World
Short Interest in CapsoVision, Inc. (NASDAQ:CV) Rises By 430.0% - MarketBeat
CapsoVision announces senior leadership transition in clinical operations By Investing.com - Investing.com Nigeria
CapsoVision announces senior leadership transition in clinical operations - Investing.com India
CapsoVision Announces Leadership Transition Plans - TipRanks
CapsoVision to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - The Manila Times
AI-Enabled Capsule Endoscopy Leader CapsoVision to Present at ROTH Healthcare Conference in NYC - Stock Titan
CapsoVision (NASDAQ:CV) Stock Price Down 2.2%Should You Sell? - MarketBeat
Financial Analysis: Longevity Health (NASDAQ:XAGE) versus CapsoVision (NASDAQ:CV) - Defense World
CapsoVision CFO Kevin Lundquist Steps Down - TipRanks
CapsoVision chief financial officer steps down; company begins search for successor - Investing.com Australia
CapsoVision CFO Kevin Lundquist Resigns - MarketWatch
Capsovision says Kevin Lundquist steps down as CFOSEC filing - MarketScreener
Ingestible Sensors Market Set for Dynamic Growth with Key Players CapsoVision, Inc., BodyCAP, etectRx - openPR.com
Head to Head Comparison: CapsoVision (NASDAQ:CV) vs. ReShape Lifesciences (OTCMKTS:RSLSD) - Defense World
Smart Pills Market Worth US$1.30 Billion By 2030 With 11.2% CAGR - Barchart.com
Smart Pills Market worth US$1.30 billion by 2030 with 11.2% CAGR - openPR.com
FY2028 EPS Estimates for CapsoVision Lowered by Roth Capital - MarketBeat
Critical Analysis: CapsoVision (NASDAQ:CV) vs. ReShape Lifesciences (OTCMKTS:RSLSD) - Defense World
Insider Transactions Reported | CapsoVision(CV)saw insider trading activity on 8/22/2025 - AInvest
FY2028 EPS Estimates for CapsoVision Cut by Roth Capital - Defense World
CapsoVision (NASDAQ:CV) Issues Earnings Results - MarketBeat
CV Forecast — Price Target — Prediction for 2026 - TradingView
CapsoVision 2025 Q2 Earnings Net Loss Narrows 12.2% - AInvest
CapsoVision Reports Second Quarter 2025 Financial Results - GlobeNewswire
CapsoVision Reports Revenue Growth and IPO Success - TipRanks
CapsoVision Revenue Jumps 17 Percent - AOL.com
Smart Pills Company Evaluation Report 2025 | Medtronic, Olympus, and CapsoVision Lead with Minimally Invasive and AI-Enhanced Medical Technologies - Yahoo Finance
CapsoVision (NASDAQ:CV) versus ReShape Lifesciences (OTCMKTS:RSLSD) Head to Head Comparison - Defense World
Reviewing ReShape Lifesciences (OTCMKTS:RSLSD) and CapsoVision (NASDAQ:CV) - Defense World
CapsoVision, Inc.'s Quiet Period Set To Expire on August 11th (NASDAQ:CV) - MarketBeat
Finanzdaten der Capsovision Inc-Aktie (CV)
Es liegen keine Finanzdaten für Capsovision Inc (CV) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.84%
0.40%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):